Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients

Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients

<b>Background:</b> The emergence of checkpoint inhibitors (CPIs) has significantly improved survival outcomes in later-stage melanoma. However, the efficacy of these treatments remains limited, with around 50% of later-stage melanoma patients experiencing recurrence. As variable response...

Full description

Saved in:
Bibliographic Details
Main Authors: Joseph C. Broderick, Alexandra M. Adams, Elizabeth L. Barbera, Spencer Van Decar, Guy T. Clifton, George E. Peoples
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Vaccines
Subjects:
melanoma
vaccine
immunotherapy
Online Access:https://www.mdpi.com/2076-393X/13/6/656
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items